Copper and Colorectal Cancer
Cancers · 31.10.2024 · 16 (21) · 3691
DOI: 10.3390/cancers16213691 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 31.10.2024. Verfasst von Maciej Małyszko und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Internal Medicine, Medical University of Warsaw, Banacha 1a, 02-097 Warsaw, Poland. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Minerals constitute only 5% of the typical human diet but are vital for health and functionality. Copper, a trace element, is absorbed by the human gut at 30–40% from diets typical of industrialized countries. The liver produces metallothioneins, which store copper. Copper is crucial for mitochondrial respiration, pigmentation, iron transport, antioxidant defense, hormone production, and extracellular matrix biosynthesis. Copper deficiency, often caused by mutations in the ATP7A gene, results in Menkes disease, an X-linked recessive disorder. On the contrary, Wilson disease is characterized by toxic copper accumulation. Cuproptosis, a unique form of cell death regulated by copper, is a subtype of necrosis induced by enhanced mitochondrial metabolism and intracellular copper accumulation. This process can reduce the malignant potential of tumor cells by inhibiting glucose metabolism. Therapeutically, copper and its complexes have shown efficacy in malignancy treatments. The disruption of copper homeostasis and excessive cuproplasia are significant in colorectal cancer development and metastasis. Therefore, manipulating copper status presents a potential therapeutic target for colorectal cancer, using copper chelators to inhibit copper formation or copper ion carriers to promote cuproptosis. This review highlights the role of copper in human physiology and pathology, emphasizing its impact on colorectal cancer and potential therapeutic strategies. Future AI-based approaches are anticipated to accelerate the development of new compounds targeting cuproptosis and copper disruption in colorectal cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Internal Medicine, Medical University of Warsaw, Banacha 1a, 02-097 Warsaw, Poland.
ORCID-Profile: Adam Przybyłkowski
Zitieren
APA
Małyszko, M., & Przybyłkowski, A. (2024). Copper and Colorectal Cancer. Cancers, 16(21), 3691. https://doi.org/10.3390/cancers16213691
Vancouver
Małyszko M, Przybyłkowski A. Copper and Colorectal Cancer. Cancers. 2024;16(21):3691. doi:10.3390/cancers16213691
BibTeX
@article{Mayszko2024,
author = {Małyszko, Maciej and Przybyłkowski, Adam},
title = {Copper and Colorectal Cancer},
journal = {Cancers},
year = {2024},
volume = {16},
number = {21},
pages = {3691},
doi = {10.3390/cancers16213691}
}
EUVIMED